ArticleJournal of clinical laboratory analysis2019
Impact of atopy on the severity and extrapulmonary manifestations of childhood Mycoplasma pneumoniae pneumonia.
Article in Journal of clinical laboratory analysis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Monocyte subsets study in children with Mycoplasma pneumoniae pneumonia.Immunologic research · 2019Trial
- Innate and adaptive immunity pathways linking Mycoplasma pneumoniae to pediatric asthma phenotypes.European journal of pediatrics · 2026Review
- A machine learning-based early in-hospital risk stratification model for severe mycoplasma pneumoniae pneumonia in children.Translational pediatrics · 2026Article
- Impact of Allergic Diseases or Obstructive Sleep Apnea Risk on SevereJournal of clinical medicine · 2026Article
- Host immune dysfunction and Mycoplasma pneumoniae immune evasion: dual drivers of pathogenesis in Mycoplasma pneumoniae pneumonia.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Review
- Clinical characteristics of Mycoplasma pneumoniae pneumonia in children with atopic constitution and risk factors for disease severity: a retrospective comparative study.Frontiers in pediatrics · 2026Article
- Inflammatory Mediation of the Association Between Latent Clinical Phenotypes and Multidimensional Outcomes in Pediatric Community-Acquired Pneumonia.Journal of inflammation research · 2026Article
- Development of a nomogram to predict acute liver injury in children withFrontiers in pediatrics · 2026Article
- Comparison of Different Corticosteroid Regimens for RefractoryInfection and drug resistance · 2026Article
- Clinical profile and risk factors for respiratory failure in children withBiomolecules & biomedicine · 2025Article
- Recurrent Infections in Allergic Pediatric Patients: An Immune System Problem? A Narrative Review.Children (Basel, Switzerland) · 2025Review
- Clinical characteristics ofPediatric investigation · 2025Article
- Exploring the pathogenetic mechanisms ofExperimental and therapeutic medicine · 2024Review
- Relationship between Atopic Disease and Acute Ocular and Systemic Outcomes in Patients with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.Ocular immunology and inflammation · 2023Article
- Association of atopy with disease severity in children withFrontiers in pediatrics · 2023Article
- Insight into the Pathogenic Mechanism of Mycoplasma pneumoniae.Current microbiology · 2022Review
- Serum amyloid a, C-reactive protein, and procalcitonin levels in children with Mycoplasma pneumoniae infection.Journal of clinical laboratory analysis · 2022Article
- Review
- The Diagnostic Value of High-Resolution Computed Tomography Features Combined with Mycoplasma Pneumoniae Ribonucleic Acid Load Detection for Refractory Mycoplasma Pneumonia.Contrast media & molecular imaging · 2022Article
- Characteristics of Lung Microbiota in Children's RefractoryThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectivesThe impact of atopy on disease severity and extrapulmonary manifestations in children with Mycoplasma pneumoniae (MP) pneumonia is unknown.
methodsPatients diagnosed with MP pneumonia between January 2016, and December 2017, were enrolled in this study. A total of 150 MP pneumonia patients were enrolled at diagnosis and divided into the atopic group (n = 48) and the nonatopic group (n = 102). Furthermore, these patients were also assessed after being divided into the pulmonary group (n = 120) and the extrapulmonary group (n = 30). Clinical characteristics, respiratory disease severity, any allergy history, and specific allergen sensitizations were collected from all patients. The serum interleukin-17 (IL-17) and total immunoglobulin E (lgE) levels were also measured.
resultsMore children in the atopic group than those in the nonatopic group presented with severe MP pneumonia, tachypnea, oxygen therapy, steroid treatment, atopic conditions including asthma attack, a previous history of asthma, decreased IL-17 levels, and increased IgE levels (all P < 0.05). When compared with those in the pulmonary group, the patients in the extrapulmonary group showed higher percentages of atopy, higher total lgE levels, and lower IL-17 levels (all P < 0.05).
conclusionsAtopy may be a risk factor for disease severity and extrapulmonary manifestations in children with MP pneumonia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.